Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System

Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System

Background: Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other...

Full description

Bibliographic Details
Main Authors: Stefan Milutinovic, Predrag Jancic, Vera Jokic, Marija Petrovic, Igor Dumic, Ambar Morales Rodriguez, Nikola Tanasijevic, Dustin Begosh-Mayne, Dragana Stanojevic, Ricardo O. Escarcega, Juan Lopez-Mattei, Xiangkun Cao
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Pharmaceuticals
Subjects:
pembrolizumab
cardiotoxicity
immune checkpoint inhibitors
FAERS
Online Access:https://www.mdpi.com/1424-8247/17/10/1372

Internet

https://www.mdpi.com/1424-8247/17/10/1372

Similar Items